The New York Times has sued the federal agency tasked with overseeing the 340B program to force the release of [...] …
Month: June 2024
Correction, Thursday, July 27, 2024, 7:00 p.m. EDT—The original version of this article mistakenly said Minnesota’s contract pharmacy access law [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
In the complex landscape of healthcare, compliance with the Health Resources and Services Administration’s (HRSA) 340B program is paramount for covered entities. As organizations strive to optimize their participation in the program, one critical aspect is preparing for HRSA audits. To shed light on this crucial process, we
…
Five new manufacturer restrictions on wholly-owned pharmacies taking effect in July will be “disastrous” for certain health center pharmacy arrangements, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two community health centers urged a federal appeals court to reverse an earlier dismissal of their lawsuit alleging four major [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The California Hospital Association (CHA) is the latest organization to raise concerns about the 340B ACCESS Act, a bill recently [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Slinger, Wisconsin. It’s a small town north of Milwaukee. If you’ve heard of it, it’s probably either because of Little Switzerland (small ski hill) or the Slinger Super Speedway (racetrack).
Read More »
SPONSORED CONTENT
TIP: Enhance your 340B program efficiency through collaborative review and impact analysis.
Asking your TPA
A prominent West Virginia Republican is considering taking legal action after a political action committee (PAC) reportedly spent $400,000-plus against [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Inflation Reduction Act (IRA) may reduce 340B margins for certain high-cost drugs and drive more transparency into the program, an influential pharmaceutical supply chain analyst who has been a frequent 340B critic told an audience of stakeholders late last
…